Replies to post #294349 on Amarin Corp Plc (AMRN)

[Number sleven]

Kiwi, Don't we also receive more than a decade of regulatory exclusivity in EU if approved.
Sleven,

[HinduKush]

Kiwi
If JELIS was qualification for obviousness in prior art in the EU wouldn't Mochida have stretched their hand out for a patent in teh EU on EPA (96% pure) for rpevention of R-IT like endpoints?
HK

[Will Lar]

Thanks Kiwi. The value of Amarin's patent portfolio will change drastically if they loss the appeal (even more than 3/30) in both US and OUS. So I am not convinced at all that they can rely on patents for OUS but not in US, maybe until they're being challenged.

I am with you on JELIS and Mochida. I maybe misleading you but I remember someone in O3 business once told me that Amarin licensed it from Mochida. But I never researched this myself.But some on this board said there is some difference between Epadel and Vascepa. It's a complete mystery to me too.